7-[3-(3-环己基-3-羟基丙基)-2,5-二氧代咪唑烷-4-基]庚酸 | 75693-75-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 7-[3-(3-环己基-3-羟基丙基)-2,5-二氧代咪唑烷-4-基]庚酸
• 英文名称: 5-(6-carboxyhexyl)-1-(3-cyclohexyl-3-hydroxypropyl) hydantoin
• 英文别名: BW 245C；245C77；BW245C；7-[3-(3-cyclohexyl-3-hydroxy-propyl)-2,5-dioxo-imidazolidin-4-yl]-heptanoic acid；5-(6-carboxyhexyl)-1-(3-cyclohexyl-3-hydroxypropyl)-hydantoin；7-[3-(3-Cyclohexyl-3-hydroxypropyl)-2,5-dioxoimidazolidin-4-yl]heptanoic acid
• CAS: 75693-75-3
• 化学式: C₁₉H₃₂N₂O₅
• mdl: MFCD31382199
• 分子量: 368.473
• InChiKey: ZIDQIOZJEJFMOH-UHFFFAOYSA-N

物化性质

• 密度：
  1.167±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  26
• 可旋转键数：
  11
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.842
• 拓扑面积：
  107
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  7-[3-(3-环己基-3-羟基丙基)-2,5-二氧代咪唑烷-4-基]庚酸 生成 1-(3-cyclohexyl-3-hydroxy-propyl)-5-(7-hydroxy-heptyl)-imidazolidine-2,4-dione
  参考文献：
  名称：

  CALDWELL, A. G.;WHITTAKER, N.;HARRIS, C. J.

  摘要：

  DOI：
• 作为产物：
  描述：

  potassium cyanate 、 1-环己基丙-2-烯-1-酮 、 2-氨基壬烷-1,9-二酸二乙酯 在 盐酸 、 sodium hydroxide 、 sodium tetrahydroborate 作用下， 生成 7-[3-(3-环己基-3-羟基丙基)-2,5-二氧代咪唑烷-4-基]庚酸
  参考文献：
  名称：

  Caldwell, A. Gordon; Harris, C. John; Stepney, Ray, Journal of the Chemical Society. Perkin transactions I, 1980, p. 495 - 505

  摘要：

  DOI：

文献信息

• Nitrogen heterocycles
  申请人：Burroughs Wellcome Co.

  公开号：US04262128A1

  公开（公告）日：1981-04-14

  Hydantoins of formula (I) ##STR1## ps have biological properties related to those of naturally occurring prostaglandins and may be used in medicine, for example in the treatment of thrombosis.

  公式(I)的咪唑二酮具有与天然前列腺素相关的生物性质，可用于医学中，例如用于治疗血栓形成。
• Pharmaceutical combinations including hydantoin derivatives, pharmaceutical formulations containing the combinations and methods of making the formulations
  申请人：THE WELLCOME FOUNDATION LIMITED

  公开号：EP0011828A1

  公开（公告）日：1980-06-11

  Combinations of an active compound selected from the class outstanding of hydantoin and thiohydantoin derivatives and their salts together with a phosphodiesterase inhibitor. Such combinations have pharmacological effects related to those of the active compound alone but these effects (other than vasodilatory effects) are potentiated by the phosphodiesterase inhibitor whilst the vasodilatory effect is not so potentiated. The combination may be used in medicine either along or in a formulation, for example in the treatment of thrombosis.

  选自海因和硫代海因衍生物及其盐类的活性化合物与磷酸二酯酶抑制剂的复方制剂。这种复方制剂的药理作用与单独使用活性化合物的药理作用相同，但磷酸二酯酶抑制剂可增强这些作用（除血管扩张作用外），而血管扩张作用则不受影响。这种复方制剂可单独或以制剂的形式用于医药领域，例如用于治疗血栓形成。
• Optically active hydantoin derivatives, their synthesis, pharmaceutical formulations containing them, and intermediates
  申请人：THE WELLCOME FOUNDATION LIMITED

  公开号：EP0019223A1

  公开（公告）日：1980-11-26

  Compounds of formula (I) having only two optically active centres, may exist as four isomers, each of which may be prepared by resolving a racemic amino-diester intermediate in the preparation thereof. The racemic amino-diester is selectively hydrolysed to the corresponding mono-ester which is acylated and subsequently selectively deacylated to produce the resolved mono-ester. Isomers of compounds of formula (I) having a particular configuration are biologically more active than the corresponding isomers having other configurations and are useful in medicine, either as the raw compound or in a pharmaceutical formulation, for example in inhibiting platelet aggregation.

  式 (I) 化合物 只有两个光学活性中心，可以存在四种异构体，每种异构体都可以通过分解制备过程中的外消旋氨基二酯中间体来制备。外消旋氨基二酯被选择性水解为相应的单酯，单酯被酰化，随后选择性脱酰化，生成已解析的单酯。 具有特定构型的式 (I) 化合物异构体比具有其他构型的相应异构体具有更高的生物活性，可作为原料化合物或药物制剂用于医药领域，例如抑制血小板聚集。
• Pharmacologically active N-amino hydantoin derivatives, their synthesis and intermediates
  申请人：THE WELLCOME FOUNDATION LIMITED

  公开号：EP0126849A1

  公开（公告）日：1984-12-05

  The hydantoins of formula (I) and their esters, amides, salts and solvates have prostaglandin mimetic and antagonistic properties rendering them useful in medicine. In formula (I) Z is hydrogen or alkyl; Z1 represents a group of formula -CH2-X-X1-X2 wherein, X is selected from -(CH2)2-, and cis and trans -CH=CH-, X' is a covalent bond or a straight or branched alkylene chain having 1 to 6 carbon atoms optionally having one of its methylene groups replaced by oxa (-0-) or thia (-S-) provided that at least one carbon atom separates the oxa or thia group from a carboxyl or -CH=CH- group, and X2 is a carboxyl group; and Z2 represents a group selected from -NH-CH2-R and -N=CH-R wherein, R is a group selected from -CO-Y and Y being a group selected from G3_8 alkyl, C3_8 alkenyl, phenyl-C1-4 alkyl and phenyl (wherein the phenyl group in both cases is optionally substituted by one or more groups independently selected from alkyl, alkoxy, nitro, halo and trihalomethyl), cycloalkyl of 4 to 8 carbon atoms, and 5- or 6- membered heterocyclic radicals containing at least one heteroatom selected from oxygen, sulphur and nitrogen; and Y' being a group selected from hydrogen, hydroxy, alkoxy and acyloxy.

  式 (I) 的 hydantoins 及其酯、酰胺、盐和溶液具有前列腺素模拟和拮抗特性，因此可用于医药。在式 (I) 中 Z 是氢或烷基； Z1 代表式-CH2-X-X1-X2 的基团，其中，X 选自-(CH2)2-、顺式和反式-CH=CH-，X'是共价键或具有 1 至 6 个碳原子的直链或支链亚烷基链，其一个亚甲基可选择被氧杂（-0-）或硫杂（-S-）取代，条件是至少有一个碳原子将氧杂或硫杂基团与羧基或-CH=CH-基团隔开，且 X2 是羧基；以及 Z2 代表选自-NH-CH2-R 和-N=CH-R 的基团，其中，R 是选自-CO-Y 和-CH=CH-R 的基团。 Y 是选自 G3_8 烷基、C3_8 烯基、苯基-C1-4 烷基和苯基（其中苯基在这两种情况下任选被一个或多个独立选自烷基、烷氧基、硝基、卤代和三卤甲基的基团取代）、4 至 8 个碳原子的环烷基和含有至少一个选自氧、硫和氮的杂原子的 5 或 6 成员杂环基的基团；以及 Y' 是选自氢、羟基、烷氧基和酰氧基的基团。
• Prostaglandin derivatives
  申请人：Research Development Corporation of Japan

  公开号：EP0182231A2

  公开（公告）日：1986-05-28

  Prostaglandin derivatives having cell membrane permeability characterized in that the carboxy group at 1-position of the prostaglandin is combined with a cell membrane permeable substance having hydroxy group or amino group through the intermediation of an ester bond to said hydroxy group or an amide bond to said amino group are novel and have improved cell membrane permeability.

  前列腺素衍生物具有细胞膜渗透性，其特征在于前列腺素 1 位上的羧基通过与所述羟基的酯键或与所述氨基的酰胺键的中介作用，与具有羟基或氨基的细胞膜渗透性物质结合。